<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">Health</journal-id><journal-title-group><journal-title>Health</journal-title></journal-title-group><issn pub-type="epub">1949-4998</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/health.2016.81006</article-id><article-id pub-id-type="publisher-id">Health-62788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiology of Sleep Disorders among Chronic Hemodialysis Patients in Senegal: A Multicentric Study
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>einabou</surname><given-names>Maiga Moussa Tondi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sidy</surname><given-names>Mohamed Seck</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Elhadj</surname><given-names>Fary Ka</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mouhamadou</surname><given-names>Moustapha Cisse</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Diop Dia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Diatou</surname><given-names>Gueye Dia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Boucar</surname><given-names>Diouf</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lamine</surname><given-names>Gueye</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Nephrology Department, University Hospital HALD, Dakar, Senegal</addr-line></aff><aff id="aff2"><addr-line>Faculty of Health Sciences, University Gaston Berger, Saint-Louis, Senegal</addr-line></aff><aff id="aff1"><addr-line>Nephrology Department, Faculty of Health Sciences, University Abdou Moumouni, Niamey, Niger</addr-line></aff><aff id="aff4"><addr-line>UMI 3189, “Environnement Santé Société UCAD”, Dakar, Senegal</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>zeinab_maiga@yahoo.fr(EMMT)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>01</month><year>2016</year></pub-date><volume>08</volume><issue>01</issue><fpage>42</fpage><lpage>48</lpage><history><date date-type="received"><day>27</day>	<month>October</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>12</month>	<year>January</year>	</date><date date-type="accepted"><day>15</day>	<month>January</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Sleep disorders (SD) are common dialysis patients and can impact their quality of life. In previous studies, black ethnicity was associated with higher incidence of SD but a few data are available in African patients. This study aimed to describe prevalence and risk factors of SD among Senegalese dialysis patients. Methods: We performed a cross-sectional study between February 15th and April 30th 2012 including 127 patients (75 males and 52 females) aged 46.8 &#177; 16.9 (16 - 85 years) and dialysed since &gt;6 months in three dialysis centres. For each patient, we assessed insomnia according to international definition, obstructive sleep apnea syndrome (OSAS) with the Berlin questionnaire, restless leg syndrome (RLS) using abridged version of Cambridge-Hopkins RLS questionnaire, and excessive daytime sleepiness (EDS) with Epworth sleepiness scale. Logistic multivariate regression was used to identify factors associated with different SD. Results: Overall prevalence of SD was 88% comprising: insomnia (64.3%), OSAS (49.1%), RLS (24.1%) and EDS (20.5%). Forty-two patients presented at least two disorders. No difference was noticed in prevalence of SD between genders (p = 0.14). Level of blood pressure were not different across patients with and without SD. Insomnia correlated with anemia, inflammation and EDS. OSAS was associated with age ≥50 years, EDS and neck circumference ≥25 cm. RLS correlated with anemia and EDS. Other parameters such as gender, dialysis vintage, KT/V, obesity, diabetes status and hypoalbuminemia were not associated with the different SD. The majority of patients had not been diagnosed before the survey and none of them was under treatment. Conclusions: Our findings are compatible with high prevalence of sleep disorders reported in other populations. Insomnia and OSAS are the most frequent SD but some patients combined many disorders. Nephrologists should be more aware of these SD in order to detect them early and provide efficient treatment.
 
</p></abstract><kwd-group><kwd>Sleep Disorders</kwd><kwd> Hemodialysis</kwd><kwd> Epidemiology</kwd><kwd> Senegal</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Chronic kidney disease (CKD) and particularly dialysis patients are exposed to diverse sleep disorders (SD) that can impact their daily quality of life and cardiovascular prognosis [<xref ref-type="bibr" rid="scirp.62788-ref1">1</xref>] . Compared to general population, prevalence of SD in CKD patients is significantly higher due to the presence of usual risk factors such as age, gender, obesity and other factors peculiar to uremia and dialysis treatment (anemia, uremic toxins, inflammation, water an sodium overload, drugs side effects) [<xref ref-type="bibr" rid="scirp.62788-ref2">2</xref>] . In fact, sleep disorders appear very early during CKD stage 1 and 2 and might worsen with decline of renal function [<xref ref-type="bibr" rid="scirp.62788-ref2">2</xref>] . In dialysis patients prevalence of SD is variable and around 80% of them complain of poor sleep quality [<xref ref-type="bibr" rid="scirp.62788-ref3">3</xref>] . Among the different SD, insomnia, sleep apnea, restless leg syndrome (RLS), and excessive daytime sleepiness (EDS) are the most frequently reported [<xref ref-type="bibr" rid="scirp.62788-ref4">4</xref>] . Furthermore, studies have shown that SD might increase the risk of cardiovascular death in patients with CKD [<xref ref-type="bibr" rid="scirp.62788-ref3">3</xref>] .</p><p>Previous studies from USA reported racial difference in incidence of SD but a few data are available in northern Africa [<xref ref-type="bibr" rid="scirp.62788-ref4">4</xref>] . This study aimed to describe prevalence and risk factors of four major SD among Senegalese dialysis patients.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>We performed a cross-sectional study between February 15<sup>th</sup> and April 30<sup>th</sup> 2012 including end-stage renal disease patients aged ≥ 16 years from three dialysis centres in Senegal (02 in Dakar the capital city and 01 in Saint-Louis). Patients who were dialysed since less than 6 months were not included and all patients were asked to give their free consent to participate in the study. After inclusion, all patients were screened for the following sleep disorders: insomnia, obstructive sleep apnea, restless legs syndrome and excessive daytime sleepiness. Insomnia was defined as difficulty in falling asleep, waking up too early, or frequent awakening with difficulty in falling asleep once again, in addition to secondary daytime impairments that relate to night time sleep difficulties [<xref ref-type="bibr" rid="scirp.62788-ref5">5</xref>] . Risk of obstructive sleep apnea syndrome (OSAS) was estimated with the Berlin questionnaire with a positive score (high risk of OSAS) considered in patients presenting two categories or more [<xref ref-type="bibr" rid="scirp.62788-ref6">6</xref>] . The restless leg syndrome (RLS) was assessed by the abridged version of Cambridge-Hopkins RLS questionnaire (RLS- SFDQ13) [<xref ref-type="bibr" rid="scirp.62788-ref7">7</xref>] . Excessive daytime sleepiness (EDS) assessed with Epworth Sleeping Scale and a score greater than 10 defined EDS [<xref ref-type="bibr" rid="scirp.62788-ref8">8</xref>] . Concomitantly, clinical (age, gender, medical history, tobacco and alcohol consumption, underlying kidney disease, blood pressure, temperature, dry weight), biochemical (serum creatinine, blood urea, hemoglobin, fasting glycemia, albuminemia, c-reactive protein, calcemia and phosphatemia) and dialysis parameters (frequency and duration of dialysis session, dry weight, interdialytic weight gain, mean KT/V) were collected from the patients’ medical records.</p><p>Descriptive and inferential statistical analyses were done with SPSS 18.0 (Chicago, IL). Data were expressed as mean standard deviation or median inerquartile range or percent according to their nature and distribution. Prevalence of each SD was estimated. Univariate and multivariate logistic regression analysis was used to identify risk factors associated with the different disorders. Insomnia, OSAS and RLS were taken as independent dichotomous variables and a model was constructed for each of them to identify covariates associated with to each sleep disorder. Excessive daily sleepiness represents a usual consequence of and was not considered as a dependent variable in the multivariate analysis. A p value ≤ 0.05 was considered as significant in all statistical tests.</p></sec><sec id="s3"><title>3. Results</title><p>We included 127 patients (75 males and 52 females) with a mean age of 46.2 &#177; 27.1 (16 - 85 years). Mean dialysis vintage was 41.4 &#177; 16.5 months (6 - 225 months). <xref ref-type="table" rid="table1">Table 1</xref> shows the clinical and biochemical characteristics of patients and their dialysis parameters.</p><p>Sleep disorders were found in 112 patients (overall prevalence of 88%) with a predominance of insomnia and obstructive sleep apnea. figure 1 presents specific prevalence of the different sleep disorders. No difference was noticed in prevalence of SD between genders (84% in men versus 94% in women; p = 0.14). More than a third of patients (34.7%) presented with at least two sleep disorders and the most frequent combinations were insomnia/EDS (16.1%), OSAS/EDS (9.8%) and RLS/insomnia (3.6%) (see figure 2).</p><p>Patients with insomnia presented significantly lower BMI than patients without insomnia (respectively 20.7 vs 28.3 kg/m<sup>2</sup>, p = 0.02) and lower serum albumin (respectively 3.0 vs 3.7 g/dL). Blood pressure levels were not different across patients with and without SD.</p><p>At univariate analysis (see table 2), insomnia was correlated to anemia (OR = 1.11 [1.07 - 3.46], p = 0.04), inflammation (OR = 1.29 [1.02 - 8.33], p = 0.05), and EDS (OR = 1.20 [1.04 - 9.54], p = 0.02). OSAS was associated with age ≥ 50 years (OR = 1.05 [1.03 - 4.51], p = 0.01), neck circumference &gt; 25 cm (OR = 1.37 [1.07 - 5.75], p = 0.01) and EDS (OR = 1.45 [1.06 - 11.95], p = 0.01). Restless leg syndrome showed significant association with anemia (OR = 3.02 [1.10 - 5.84], p = 0.03) and EDS (OR = 1.44 [1.01 - 7.90], p = 0.04).</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Prevalence of different forms of sleep disorders</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-8203508x7.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Association of different forms of sleep disorders</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-8203508x8.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical and biochemical characteristic of patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Mean &#177; SD</th><th align="center" valign="middle" >Percent</th></tr></thead><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >46.2 &#177; 27.1 (16 - 85)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender (% male)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >59%</td></tr><tr><td align="center" valign="middle" >Dialysis vintage (months)</td><td align="center" valign="middle" >41.4 &#177;16.5 (6 - 125)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Dry Weight (kg)</td><td align="center" valign="middle" >50.7 &#177; 26.3 (46 - 83)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Interdialytic weight gain (kg)</td><td align="center" valign="middle" >1.9 &#177; 2.5 (0.3 - 3.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >65.30%</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >33.80%</td></tr><tr><td align="center" valign="middle" >Body mass index</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18.5 kg/m<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28.90%</td></tr><tr><td align="center" valign="middle" >18.5 to 25 kg/m<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >52.90%</td></tr><tr><td align="center" valign="middle" >&gt;25 kg/m<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >18.20%</td></tr><tr><td align="center" valign="middle" >Weekly dialysis hours</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥12 h</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >64.70%</td></tr><tr><td align="center" valign="middle" >&lt;12 h</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >34.60%</td></tr><tr><td align="center" valign="middle" >KT/V</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥1.2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >77.20%</td></tr><tr><td align="center" valign="middle" >&lt;1.2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22.80%</td></tr><tr><td align="center" valign="middle" >C-reactive protein (mg/L)</td><td align="center" valign="middle" >5.2 &#177; 9.5 (0.42 - 48.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Serum albumin (g/dL)</td><td align="center" valign="middle" >39 &#177; 25.8 (18.7 - 46.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Serum hemoglobin (g/dL)</td><td align="center" valign="middle" >09.5 &#177; 10.2 (0.63 - 14.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Phosphatemia (mg/dL)</td><td align="center" valign="middle" >4.6 &#177; 3.5 (2.43 - 6.25)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Calcemia (mg/dL)</td><td align="center" valign="middle" >2.1 &#177; 2.6 (75 - 106)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Univariate analysis of factors associated with sleep disorders</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="2"  >Insomnia</th><th align="center" valign="middle"  colspan="2"  >Sleep apnea syndrome</th><th align="center" valign="middle"  colspan="2"  >Restless legs syndrome</th></tr></thead><tr><td align="center" valign="middle" >OR [95% CI]</td><td align="center" valign="middle" >p-value</td><td align="center" valign="middle" >OR [95% CI]</td><td align="center" valign="middle" >p-value</td><td align="center" valign="middle" >OR [95% CI]</td><td align="center" valign="middle" >p-value</td></tr><tr><td align="center" valign="middle" >Age ≥ 50 years</td><td align="center" valign="middle" >1.10 [0.90 - 3.06]</td><td align="center" valign="middle" >0.21</td><td align="center" valign="middle" >1.05 [1.03 - 4.51]</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >1.21 [0.75 - 3.45]</td><td align="center" valign="middle" >0.08</td></tr><tr><td align="center" valign="middle" >Gender (Male)</td><td align="center" valign="middle" >1.13 [0.26 - 7.94]</td><td align="center" valign="middle" >0.67</td><td align="center" valign="middle" >1.09 [0.58 - 4.25]</td><td align="center" valign="middle" >0.61</td><td align="center" valign="middle" >1.16 [0.51 - 5.52]</td><td align="center" valign="middle" >0.49</td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" >0.86 [0.97 - 1.03]</td><td align="center" valign="middle" >0.78</td><td align="center" valign="middle" >1.85 [0.61 - 4.36]</td><td align="center" valign="middle" >0.23</td><td align="center" valign="middle" >0.95 [0.50 - 1.78]</td><td align="center" valign="middle" >0.81</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >0.78 [0.50 - 1.74]</td><td align="center" valign="middle" >0.26</td><td align="center" valign="middle" >0.99 [0.72 - 2.64]</td><td align="center" valign="middle" >0.17</td><td align="center" valign="middle" >0.45 [0.34 - 1.84]</td><td align="center" valign="middle" >0.52</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >1.20 [0.50 - 4.78]</td><td align="center" valign="middle" >0.56</td><td align="center" valign="middle" >1.23 [0.15 - 3.94]</td><td align="center" valign="middle" >0.86</td><td align="center" valign="middle" >1.17 [0.65 - 3.28]</td><td align="center" valign="middle" >0.65</td></tr><tr><td align="center" valign="middle" >EDS<sup>a</sup></td><td align="center" valign="middle" >1.20 [1.04 - 9.54]</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >1.45 [1.06 - 11.95]</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >1.44 [1.01 - 7.90]</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >Anemia</td><td align="center" valign="middle" >1.11 [1.07 - 3.46]</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >1.27 [0.59 - 7.40]</td><td align="center" valign="middle" >0.89</td><td align="center" valign="middle" >3.02 [1.10 - 5.84]</td><td align="center" valign="middle" >0.03</td></tr><tr><td align="center" valign="middle" >Inflammation<sup>b</sup></td><td align="center" valign="middle" >1.29 [1.02 - 8.33]</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >1.02 [0.36 - 9.43]</td><td align="center" valign="middle" >0.21</td><td align="center" valign="middle" >0.94 [0.35 - 1.62]</td><td align="center" valign="middle" >0.38</td></tr><tr><td align="center" valign="middle" >Hypoalbuminemia</td><td align="center" valign="middle" >0.88 [0.03 - 3.46]</td><td align="center" valign="middle" >0.67</td><td align="center" valign="middle" >1.33 [0.60 - 3.08]</td><td align="center" valign="middle" >0.55</td><td align="center" valign="middle" >1.70 [0.66 - 6.98]</td><td align="center" valign="middle" >0.42</td></tr><tr><td align="center" valign="middle" >Low dialysis quality<sup>c</sup></td><td align="center" valign="middle" >1.01 [0.01 - 10.67]</td><td align="center" valign="middle" >0.82</td><td align="center" valign="middle" >1.05 [0.38 - 9.45]</td><td align="center" valign="middle" >0.35</td><td align="center" valign="middle" >1.10 [0.25 - 15.12]</td><td align="center" valign="middle" >0.39</td></tr><tr><td align="center" valign="middle" >NC<sup>d </sup>≥ 25 cm</td><td align="center" valign="middle" >1.06 [0.08 - 8.62]</td><td align="center" valign="middle" >0.50</td><td align="center" valign="middle" >1.37 [1.07 - 5.75]</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >0.92 [0.10 - 9.06]</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >IDWG<sup>e</sup> ≥ 2.5 kg</td><td align="center" valign="middle" >1.01 [0.63 - 1.99]</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >0.92 [0.15 - 6.47]</td><td align="center" valign="middle" >0.29</td><td align="center" valign="middle" >0.95 [0.07 - 8.12]</td><td align="center" valign="middle" >0.43</td></tr></tbody></table></table-wrap><p><sup>a</sup>EDS = excessive daytime sleepness; <sup>b</sup>Inflammation = C-reactive protein ≥ 6 mg/l; <sup>c</sup>mean monthly KT/V &lt; 1.2; <sup>d</sup>NC = neck circumference; <sup>e</sup>IDWG = interdialytic weight gain.</p><p>However, the multivariate analysis (see table 3) identified anemia (OR = 1.31 [1.04 - 2.76], p = 0.03), EDS (OR = 1.28 [1.02 - 5.57], p = 0.02) and inflammation (OR = 1.23 [1.05 - 4.63], p = 0.01) as factors associated with insomnia. Neck circumference &gt; 25 cm (OR = 1.25 [1.02 - 3.62], p = 0.03), age ≥ 50 years (OR = 1.08 [1.01 - 3.55], p = 0.02) and EDS (OR = 1.18 [1.02 - 8.25], p = 0.02) were still correlated to OSAS. Also, anemia was the strongest risk factor for RLS (OR = 3.32 [1.04 - 8.33], p = 0.05) followed by EDS (OR = 1.44 [1.05 - 6.50], p = 0.03). Other parameters such as gender, dialysis vintage, KT/V, obesity, diabetes status and hypoal- buminemia did not show significant association with any of the four studied disorders. The majority of patients were not diagnosed before the survey and none of them was under treatment.</p></sec><sec id="s4"><title>4. Discussion</title><p>This study shows that sleep disorders are very common in Senegalese patients undergo dialysis. The overall prevalence of SD was even higher than what was reported in Asian or European patients, ranging from 41% to 86% [<xref ref-type="bibr" rid="scirp.62788-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref10">10</xref>] . Insomnia which concerned more than half of our patients was also found in majority of previous studies as the most frequent disorder in dialysis patients [<xref ref-type="bibr" rid="scirp.62788-ref4">4</xref>] . It was correlated with anemia, EDS and inflammation. Furthermore, in comparison to general population dialysis patients are more exposed to insomnia due to other SD like OSAS or RLS and the impact in patient’s daily activity can be worsened with presence of excessive sleepiness [<xref ref-type="bibr" rid="scirp.62788-ref11">11</xref>] .</p><p>The OSAS was the second SD in our patients and its prevalence is comparable to data reported by other studies in Spain and Switzerland [<xref ref-type="bibr" rid="scirp.62788-ref12">12</xref>] .</p><p>Other authors had found much lower prevalence in patients from Saudi Arabia (35.7%) [<xref ref-type="bibr" rid="scirp.62788-ref13">13</xref>] , Egypt (31.8%) [<xref ref-type="bibr" rid="scirp.62788-ref14">14</xref>] , Italy (23.6%) [<xref ref-type="bibr" rid="scirp.62788-ref11">11</xref>] , Brazil (36%) [<xref ref-type="bibr" rid="scirp.62788-ref15">15</xref>] , Germany (16.4%) [<xref ref-type="bibr" rid="scirp.62788-ref15">15</xref>] , China (14%) [<xref ref-type="bibr" rid="scirp.62788-ref16">16</xref>] , and USA (3.4%) [<xref ref-type="bibr" rid="scirp.62788-ref17">17</xref>] . Like in our patients, the association between OSAS and neck circumference was confirmed in many previous studies [<xref ref-type="bibr" rid="scirp.62788-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref12">12</xref>] . One of the hypotheses to explain the high prevalence of OASA in dialysis patients is fluid overload combined to metabolic acidosis for chronic obstructive SAS or uremic toxins accumulation in the case of SAS central type [<xref ref-type="bibr" rid="scirp.62788-ref18">18</xref>] .</p><p>Restless legs syndrome and EDS were present respectively in 24.1% and 20.5% of our patients contrasting with the lower frequency of RLS described in African American patients [<xref ref-type="bibr" rid="scirp.62788-ref19">19</xref>] . In the literature, reported prevalence of RLS range from 6 to 80% [<xref ref-type="bibr" rid="scirp.62788-ref20">20</xref>] . Patients with OSAS and RLS commonly suffer from excessive sleepiness during daytime [<xref ref-type="bibr" rid="scirp.62788-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref21">21</xref>] .</p><p>The main reason for the great variability in prevalence of SD between studies is related to the diagnosis methods used and the difference in the populations’ characteristics. Berlin questionnaire is widely used by authors in dialysis patients but polysomnography is the gold standard for diagnosis of OSAS [<xref ref-type="bibr" rid="scirp.62788-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref15">15</xref>] . Also,</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Multivariate analysis of factors associated with sleep disorders</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="3"  >Insomnia</th><th align="center" valign="middle"  colspan="3"  >Sleep apnea syndrome</th><th align="center" valign="middle"  colspan="4"  >Restless legs syndrome</th></tr></thead><tr><td align="center" valign="middle" >OR</td><td align="center" valign="middle" >[95% CI]</td><td align="center" valign="middle" >p-value</td><td align="center" valign="middle" >OR</td><td align="center" valign="middle" >[95% CI]</td><td align="center" valign="middle" >p-value</td><td align="center" valign="middle" >OR</td><td align="center" valign="middle" >[95% CI]</td><td align="center" valign="middle" >p-value</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age ≥ 50 years</td><td align="center" valign="middle" >1.20</td><td align="center" valign="middle" >0.59 - 10.76</td><td align="center" valign="middle" >0.72</td><td align="center" valign="middle" >1.08</td><td align="center" valign="middle" >1.01 - 3.55</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >1.13</td><td align="center" valign="middle" >0.85 - 9.65</td><td align="center" valign="middle" >0.40</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender (male)</td><td align="center" valign="middle" >1.43</td><td align="center" valign="middle" >0.26 - 7.94</td><td align="center" valign="middle" >0.64</td><td align="center" valign="middle" >1.05</td><td align="center" valign="middle" >0.45 - 10.20</td><td align="center" valign="middle" >0.40</td><td align="center" valign="middle" >1.62</td><td align="center" valign="middle" >0.16 - 7.42</td><td align="center" valign="middle" >0.49</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" >1.10</td><td align="center" valign="middle" >0.72 - 1.03</td><td align="center" valign="middle" >0.91</td><td align="center" valign="middle" >1.24</td><td align="center" valign="middle" >0.82 - 14.51</td><td align="center" valign="middle" >0.42</td><td align="center" valign="middle" >1.41</td><td align="center" valign="middle" >0.25 - 13.95</td><td align="center" valign="middle" >0.18</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >0.78</td><td align="center" valign="middle" >0.50 - 1.22</td><td align="center" valign="middle" >0.78</td><td align="center" valign="middle" >1.53</td><td align="center" valign="middle" >0.87 - 7.11</td><td align="center" valign="middle" >0.18</td><td align="center" valign="middle" >1.02</td><td align="center" valign="middle" >0.34 - 2.56</td><td align="center" valign="middle" >0.32</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Anemia</td><td align="center" valign="middle" >1.31</td><td align="center" valign="middle" >1.04 - 2.76</td><td align="center" valign="middle" >0.03</td><td align="center" valign="middle" >1.45</td><td align="center" valign="middle" >0.14 - 6.77</td><td align="center" valign="middle" >0.70</td><td align="center" valign="middle" >3.32</td><td align="center" valign="middle" >1.04 - 8.33</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Inflammation<sup>a</sup></td><td align="center" valign="middle" >1.23</td><td align="center" valign="middle" >1.05 - 4.63</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >1.25</td><td align="center" valign="middle" >0.68 - 7.25</td><td align="center" valign="middle" >0.40</td><td align="center" valign="middle" >1.12</td><td align="center" valign="middle" >0.34 - 2.56</td><td align="center" valign="middle" >0.32</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low dialysis quality<sup>b</sup></td><td align="center" valign="middle" >1.20</td><td align="center" valign="middle" >0.96 - 1.87</td><td align="center" valign="middle" >0.47</td><td align="center" valign="middle" >0.47</td><td align="center" valign="middle" >0.24 - 2.68</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >0.48</td><td align="center" valign="middle" >0.70 - 1.31</td><td align="center" valign="middle" >0.29</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IDWG<sup>c</sup> ≥ 2.5 kg</td><td align="center" valign="middle" >1.50</td><td align="center" valign="middle" >0.27 - 6.85</td><td align="center" valign="middle" >0.56</td><td align="center" valign="middle" >1.04</td><td align="center" valign="middle" >0.92 - 3.56</td><td align="center" valign="middle" >0.50</td><td align="center" valign="middle" >0.69</td><td align="center" valign="middle" >0.55 - 1.54</td><td align="center" valign="middle" >0.88</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NC<sup>d </sup>≥ 25 cm</td><td align="center" valign="middle" >1.06</td><td align="center" valign="middle" >0.55 -7.62</td><td align="center" valign="middle" >0.23</td><td align="center" valign="middle" >1.25</td><td align="center" valign="middle" >1.02 - 3.62</td><td align="center" valign="middle" >0.03</td><td align="center" valign="middle" >1.01</td><td align="center" valign="middle" >0.25 - 9.83</td><td align="center" valign="middle" >0.27</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >EDS<sup>e</sup></td><td align="center" valign="middle" >1.28</td><td align="center" valign="middle" >1.02 - 5.57</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >1.18</td><td align="center" valign="middle" >1.02 - 8.25</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >1.44</td><td align="center" valign="middle" >1.05 - 6.50</td><td align="center" valign="middle" >0.03</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p><sup>a</sup>Inflammation = C-reactive protein ≥ 6 mg/l; <sup>b</sup>mean monthly KT/V &lt; 1.2; <sup>c</sup>IDWG= interdialytic weight gain; <sup>d</sup>NC= neck circumference; <sup>e</sup>EDS = excessive daytime sleepness.</p><p>we used an abridged version of Cambridge questionnaire which was shown to more accurate than IRLSSG questionnaire extensively studied in many countries [<xref ref-type="bibr" rid="scirp.62788-ref7">7</xref>] .</p><p>Though many factors such as diabetes, neuropathy, uremia, psychiatric disorders, and anemia were identified as associated to SD [<xref ref-type="bibr" rid="scirp.62788-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref23">23</xref>] , the only risk factors significantly associated with sleep disorders were age (for OSAS), neck circumference (for OSAS), anemia (for insomnia, OSAS and RLS) and inflammation (for insomnia) while as EDS was correlated with all other SD.</p><p>Despite the interesting findings, our study presents many limitations due firstly to its small sample size. Moreover, assessment of sleep disorders based on questionnaires may have overestimated or underestimated the true prevalence of diseases. Finally, because of the cross-sectional design, any significant association found with regression analysis do not imply any causal effect.</p><p>However, these differences in measurement tools should not hide the potential negative impact of SD on patients’quality of life and survival [<xref ref-type="bibr" rid="scirp.62788-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.62788-ref24">24</xref>] .</p></sec><sec id="s5"><title>5. Conclusion</title><p>This study shows that in Senegalese patients undergoing dialysis, sleep disorders are as common as reported in other populations. Insomnia and OSAS are the most frequent SD but one third of patients combined many disorders. Anemia and inflammation represent the main risk factors for insomnia and RLS while age and neck circumference &gt; 25 cm are associated with OSAS. Excessive daily sleepiness is a common consequence of other SD. Nephrologists and dialysis nurses should be more aware of these diseases in order to detect them early and provide efficient treatment.</p></sec><sec id="s6"><title>Cite this paper</title><p>Zeinabou Maiga MoussaTondi,Sidy MohamedSeck,Elhadj FaryKa,Mouhamadou MoustaphaCisse,Amadou DiopDia,Diatou GueyeDia,BoucarDiouf,LamineGueye, (2016) Epidemiology of Sleep Disorders among Chronic Hemodialysis Patients in Senegal: A Multicentric Study. Health,08,42-48. doi: 10.4236/health.2016.81006</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.62788-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Khalil, E.S., Mohamed, E.I., Khalil, G.I., et al. (2013) Effects of Sleep Disordered Breathing on Functional Capacity and Quality of Life in Chronic Kidney Disease Egyptian Patients. Sleep Breath, 17, 621-628. http://dx.doi.org/10.1007/s11325-012-0732-0</mixed-citation></ref><ref id="scirp.62788-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Plantinga, L., Lee, K., Inker, L.A., et al. (2011) Association of Sleep-Related Problems with CKD in the United States, 2005-2008. American Journal Kidney Disease, 58, 554-564. http://dx.doi.org/10.1053/j.ajkd.2011.05.024</mixed-citation></ref><ref id="scirp.62788-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bastos, J.P., Sousa, R.B., Nepomuceno, L.A., Gutierrez-Adrianzen, O.A., et al. (2007) Sleep Disturbances in Patients on Maintenance Hemodialysis: Role of Dialysis Shift. Revista Associacao Medica Brasileira, 53, 492-496. http://dx.doi.org/10.1590/S0104-42302007000600014</mixed-citation></ref><ref id="scirp.62788-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ezzat, H. and Mohab, A. (2015) Prevalence of Sleep Disorders among ESRD Patients. Renal Failure, 11, 1-7. http://dx.doi.org/10.3109/0886022x.2015.1044401</mixed-citation></ref><ref id="scirp.62788-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Association, A.A.S.D. (1997) International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manuals. American Sleep Disorders Association, Rochester.</mixed-citation></ref><ref id="scirp.62788-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Netzer, N.C., Stoohs, R.A., Netzer, C.M., et al. (1999) Using the Berlin Questionnaire to Identify Patients at Risk for the Sleep Apnea Syndrome. Annals of Internal Medicine, 131, 485-491. http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00002</mixed-citation></ref><ref id="scirp.62788-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gholamrezaei, A. and Saadatnia, M. (2013) Application of the Cambridge-Hopkins Diagnostic Questionnaire for Investigating Restless Legs Syndrome in Patients with Chronic Renal Failure. Sleep Medicine, 14, 225. http://dx.doi.org/10.1016/j.sleep.2012.09.002</mixed-citation></ref><ref id="scirp.62788-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Johns</surname><given-names> M.W. </given-names></name>,<etal>et al</etal>. (<year>1991</year>)<article-title>A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale</article-title><source> Sleep</source><volume> 14</volume>,<fpage> 540</fpage>-<lpage> 545</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.62788-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Parker, K.P. (2003) Sleep Disturbances in Dialysis Patients. Sleep Medicine Review, 7, 131-143. http://dx.doi.org/10.1053/smrv.2001.0240</mixed-citation></ref><ref id="scirp.62788-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Masoumi, M., Naini, A.E., Aghaghazvini, R., et al. (2013) Sleep Quality in Patients on Maintenance Hemodialysis and Peritoneal Dialysis. International Journal of Preventive Medicine, 4, 165-172.</mixed-citation></ref><ref id="scirp.62788-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Merlino, G., Gigli, G.L. and Valente, M. (2008) Sleep Disturbances in Dialysis Patients. Journal of Nephrology, 21, S66-S70.</mixed-citation></ref><ref id="scirp.62788-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Muller, M.E., Heinzer, R., Pruijm, M., et al. (2012) Troubles du sommeil chez des patients présentant une insuffisance rénale chronique. Revue Médicale Suisse, 8, 458-461.</mixed-citation></ref><ref id="scirp.62788-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Al-Jahdali</surname><given-names> H. </given-names></name>,<etal>et al</etal>. (<year>2012</year>)<article-title>Prevalence of Sleep Apnea and Excessive Day Time Sleepiness in Patients with End-Stage Renal Disease on Dialysis</article-title><source> Saudi Journal of Kidney Diseases and Transplantation</source><volume> 23</volume>,<fpage> 251</fpage>-<lpage>261</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.62788-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sabry, A.A., Abo-Zenah, H., Wafa, E., et al. (2010) Sleep Disorders in Hemodialysis Patients. Saudi Journal of Kidney Diseases and Transplantation, 21, 300-305.</mixed-citation></ref><ref id="scirp.62788-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kuhlmann, U., Becker, H.F., Birkhahn, M., et al. (2000) Sleep-Apnea in Patients with End-Stage Renal Disease and Objective Results. Clinical Nephrology, 53, 460-466.</mixed-citation></ref><ref id="scirp.62788-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hui, D.S., Wong, T.Y., Li, T.S., et al. (2002) Prevalence of Sleep Disturbances in Chinese Patients with End Stage Renal Failure on Maintenance Hemodialysis. Medical Sciences Monitoring, 8, CR331-CR336.</mixed-citation></ref><ref id="scirp.62788-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sim, J.J., Rasgon, S.A., Kujubu, D.A., et al. (2009) Sleep Apnea in Early and Advanced Chronic Kidney Disease: Kaiser Permanente Southern California Cohort. Chest, 135, 710-716. http://dx.doi.org/10.1378/chest.08-2248</mixed-citation></ref><ref id="scirp.62788-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Elias, R.M., Chan, C.T., Paul, N., et al. (2013) Relationship of Pharyngeal Water Content and Jugular Volume with Severity of Obstructive Sleep Apnea in Renal Failure. Nephrology Dialysis and Transplantation, 28, 937-944.http://dx.doi.org/10.1093/ndt/gfs473</mixed-citation></ref><ref id="scirp.62788-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kutner, N.G., Zhang, R., Huang, Y., et al. (2012) Racial Differences in Restless Legs Symptoms and Serum Ferritin in an Incident Dialysis Patient Cohort. International Journal of Urology Nephrology, 44, 1825-1831.http://dx.doi.org/10.1007/s11255-011-0108-6</mixed-citation></ref><ref id="scirp.62788-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yazdi, Z., Sadeghniiat-Haghighi, K., Kazemifar, A.M., et al. Saudi Journal of Kidney Diseases and Transplantation, 26, 625-660.</mixed-citation></ref><ref id="scirp.62788-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Losso, R.L., Minhoto, G.R. and Riella, M.C. (2015) Sleep Disorders in Patients with End-Stage Renal Disease Undergoing Dialysis: Comparison between Hemodialysis, Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis. International Journal of Urology Nephrology, 47, 369-375. http://dx.doi.org/10.1007/s11255-014-0860-5</mixed-citation></ref><ref id="scirp.62788-ref22"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parker</surname><given-names> K.P. </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>Sleep and Dialysis: A Research-Based Review of the Literature</article-title><source> American Nephrology Nurses’ Association Journal</source><volume> 6</volume>,<fpage> 7626</fpage>-<lpage>7639</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.62788-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sabbatini, M., Pisani, A., Crispo, A., et al. (2002) Sleep Quality in Patients with Chronic Renal Failure: A 3-Year Longitudinal Study. Sleep Medicine, 9, 240-246. http://dx.doi.org/10.1016/j.sleep.2007.04.005</mixed-citation></ref><ref id="scirp.62788-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Elder, S.J., Pisoni, R.L., Akizawa, T., et al. (2008) Sleep Quality Predicts Quality of Life and Mortality Risk in Haemodialysis Patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis and Transplantation, 23, 998-1004. http://dx.doi.org/10.1093/ndt/gfm630</mixed-citation></ref></ref-list></back></article>